These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17428517)

  • 21. The role of receptors in the HIV-1 entry process.
    Jones R; Nelson M
    Eur J Med Res; 2007 Oct; 12(9):391-6. PubMed ID: 17933719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Originality of entry inhibitors].
    Izopet J
    Med Mal Infect; 2009 Oct; 39(10 Suppl 1):H1-4. PubMed ID: 19837343
    [No Abstract]   [Full Text] [Related]  

  • 23. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli.
    Pusch O; Kalyanaraman R; Tucker LD; Wells JM; Ramratnam B; Boden D
    AIDS; 2006 Oct; 20(15):1917-22. PubMed ID: 16988512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The epidemiology of HIV coreceptor tropism.
    Hoffmann C
    Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells.
    Sullivan WM; Dorr P; Perros M; Hudson R; Leif J; Luzuriaga K; Clapham PR
    Arch Virol; 2008; 153(2):363-6. PubMed ID: 18074097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor.
    Boggiano C; Jiang S; Lu H; Zhao Q; Liu S; Binley J; Blondelle SE
    Biochem Biophys Res Commun; 2006 Sep; 347(4):909-15. PubMed ID: 16854380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
    Telwatte S; Moore K; Johnson A; Tyssen D; Sterjovski J; Aldunate M; Gorry PR; Ramsland PA; Lewis GR; Paull JR; Sonza S; Tachedjian G
    Antiviral Res; 2011 Jun; 90(3):195-9. PubMed ID: 21459115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
    Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
    Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
    Huskens D; Vermeire K; Profy AT; Schols D
    Antiviral Res; 2009 Oct; 84(1):38-47. PubMed ID: 19664662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants.
    Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
    AIDS; 2011 Oct; 25(16):1971-9. PubMed ID: 21811139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1.
    Pirrone V; Wigdahl B; Krebs FC
    Antiviral Res; 2011 Jun; 90(3):168-82. PubMed ID: 21439325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The X4 files.
    Huff B
    GMHC Treat Issues; 2004; 18(7-8):4-6. PubMed ID: 15473042
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.
    Garrido C; Roulet V; Chueca N; Poveda E; Aguilera A; Skrabal K; Zahonero N; Carlos S; García F; Faudon JL; Soriano V; de Mendoza C
    J Clin Microbiol; 2008 Mar; 46(3):887-91. PubMed ID: 18199789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection.
    Frank I; Robbiani M
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):204-12. PubMed ID: 21084994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two genotypic algorithms to determine HIV-1 tropism.
    Soulié C; Derache A; Aimé C; Marcelin AG; Carcelain G; Simon A; Katlama C; Calvez V
    HIV Med; 2008 Jan; 9(1):1-5. PubMed ID: 18199166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.
    Ketas TJ; Kuhmann SE; Palmer A; Zurita J; He W; Ahuja SK; Klasse PJ; Moore JP
    Virology; 2007 Aug; 364(2):281-90. PubMed ID: 17428518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
    Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors.
    Dong MX; Lu L; Li H; Wang X; Lu H; Jiang S; Dai QY
    Bioorg Med Chem Lett; 2012 May; 22(9):3284-6. PubMed ID: 22464131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
    Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
    Virol J; 2008 May; 5():56. PubMed ID: 18452606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.